Sort
48,018 grants matching “immunotherapy”
SPORE in Skin Cancer
$2,712,962Brigham And Women'S Hospital · P50 · FY2001 · CA
Pediatric Brain Tumor Consortium (PBTC)
$2,711,401Arzu Onar-Thomas · St. Jude Children'S Research Hospital · UM1 · FY2016 · CA
Interleukin-15 Production for Treatment of Patients with Metastatic Malignancy
$2,710,901Thomas Waldmann · Division Of Basic Sciences - Nci · ZIB · FY2017 · CA
Immunohistochemical and genomic analysis of tumors
$2,706,048Markku Miettinen · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Biology and structure of pMHC receptors functioning as mechanosensors in the [alpha][beta] T-cell lineage
$2,705,373Ellis L Reinherz · Dana-Farber Cancer Inst · P01 · FY2025 · AI
Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)
$2,702,613James R. Heath · Institute For Systems Biology · U54 · FY2022 · CA
COG NCTN Network Group Operations Center
$2,702,029Richard Aplenc · Children'S Hosp Of Philadelphia · U10 · FY2020 · CA
A Global Map of Interactions Among Human Cell Surface Proteins and Secreted Ligands
$2,701,375Kai G Zinn · California Institute Of Technology · R01 · FY2023 · GM
Midwest Murine-Tissue Mapping Center (MM-TMC)
$2,700,000David A Bernlohr · University Of Minnesota · U54 · FY2023 · AG
Midwest Murine-Tissue Mapping Center (MM-TMC)
$2,700,000David A Bernlohr · University Of Minnesota · U54 · FY2022 · AG
Midwest Murine-Tissue Mapping Center (MM-TMC)
$2,700,000Paul D. Robbins · University Of Minnesota · U54 · FY2025 · AG
Midwest Murine-Tissue Mapping Center (MM-TMC)
$2,700,000Paul D. Robbins · University Of Minnesota · U54 · FY2024 · AG
Engineering T cells to Provide Durable Control of HIV-1 Replication
$2,699,182James L Riley · University Of Pennsylvania · U19 · FY2022 · AI
Allogeneic Immunotherapy for cancer and nonmalignant hematological disorders
$2,693,826Richard Childs · National Heart, Lung, And Blood Institute · ZIA · FY2011 · HL
Bone Marrow Transplantation in Human Disease
$2,692,393Johns Hopkins University · P01 · FY2004 · CA
Immunotherapy targeting the HPA axis in Alzheimerâs disease
$2,689,784Todd E. Golde · University Of Florida · RF1 · FY2019 · AG
Establishment of a Human Microphysiological System to Elucidate Cellular Mechanisms Underlying Vulnerability to AD
$2,683,965Tracy L Young-Pearse · Brigham And Women'S Hospital · RF1 · FY2025 · NS
Understanding and Overcoming T cell Immunosuppression in Glioblastoma
$2,680,832E. Antonio Chiocca · Brigham And Women'S Hospital · P01 · FY2024 · CA
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
$2,680,709Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2022 · AG
ExpLoiting thErapeutic VulnerAbilities in hepaTocEllular carcinoma (ELEVATE)
$2,678,459Devanand Sarkar · Virginia Commonwealth University · P01 · FY2024 · CA
Comprehensive Cancer Center Program at Fox Chase
$2,675,570Richard I Fisher · Research Inst Of Fox Chase Can Ctr · P30 · FY2016 · CA
Building on the success of the adoptive immunotherapy of cancer
$2,673,969Nicholas Restifo · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Bone Marrow Transplantation in Human Disease
$2,670,385Johns Hopkins University · P01 · FY2003 · CA
Cancer Immunotherapy Trials Network Central Operations and Statistical Center
$2,667,211Martin Cheever · Fred Hutchinson Cancer Research Center · U01 · FY2014 · CA
Skeletal Disorders and Mineral Homeostasis Section
$2,663,809Michael Collins · National Institute Of Dental & Craniofacial Research · ZIA · FY2020 · DE